Insurance Status Affects Survival Rate in Hodgkin's

Results of a troubling new study show just how much insurance matters when discussing outcomes in a largely curable cancer.

According to the study, published in the journal Cancer, patients diagnosed with Hodgkin's lymphoma who either have Medicaid or do not have insurance do much worse than patients with so-called 'favorable' insurance.

These researchers analyzed the data from 45,777 patients with stage I to IV Hodgkin lymphoma from the National Cancer Data Base. Of those:

  • 7.1% were uninsured
  • 17% had Medicaid
  • 66.3% had private insurance
  • 8.2% had managed care
  • 1.1% had Medicare

Patients with Medicaid or who did not have insurance were not only diagnosed at a more advanced stage, they also had higher comorbidity scores, were more likely to have B symptoms, and were in a lower education/income quartile.

Notably, patients with the unfavorable insurance status were found to be less likely to receive radiation therapy, and to begin chemotherapy as quickly as those with favorable insurance.

The five year overall survival rates between the two groups were also very telling. The rate for patients with unfavorable insurance or none at all was 54 percent, while for patients with favorable insurance had a rate of 87 percent.

The researchers conclude that targeting patients with unfavorable insurance would help improve outcomes.

Source: Cancer

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap